AC Immune SA (ACIU) & TG Therapeutics (TGTX) Head to Head Contrast
AC Immune SA (NASDAQ: ACIU) and TG Therapeutics (NASDAQ:TGTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.
Valuation & Earnings
This table compares AC Immune SA and TG Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|AC Immune SA||$5.83 million||100.20||-$34.66 million||N/A||N/A|
|TG Therapeutics||$152,381.00||4,886.47||-$104.96 million||($1.95)||-6.13|
AC Immune SA has higher revenue and earnings than TG Therapeutics.
This is a summary of recent ratings for AC Immune SA and TG Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AC Immune SA||0||0||3||0||3.00|
AC Immune SA presently has a consensus price target of $21.67, indicating a potential upside of 111.59%. TG Therapeutics has a consensus price target of $26.89, indicating a potential upside of 125.01%. Given TG Therapeutics’ higher probable upside, analysts clearly believe TG Therapeutics is more favorable than AC Immune SA.
Insider & Institutional Ownership
18.1% of AC Immune SA shares are owned by institutional investors. Comparatively, 49.9% of TG Therapeutics shares are owned by institutional investors. 16.7% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares AC Immune SA and TG Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AC Immune SA||N/A||N/A||N/A|
AC Immune SA Company Profile
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
TG Therapeutics Company Profile
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
Receive News & Stock Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related stocks with our FREE daily email newsletter.